| AMLYPAVE ALEXION PHARMACEUTICALS INC.
2183974 07 Apr 2022 | on 04 Oct 2024 | Class 005 Class 005 Pharmaceutical Products Pharmaceutical preparations for the treatment of autoimmune diseases and disorders, protein aggregation-related diseases and disorders, namely, diseases caused by protein deposition, abnormal proteins, production and aggregation-related diseases and disorders, namely, amyloidosis, and neurodegenerative diseases and disorders. | | | AMLYCAS PROTHENA THERAPEUTICS LIMITED
1890908 29 Mar 2018 | on 07 Jan 2020 | Class 005 Class 005 Pharmaceutical Products Biopharmaceuticals and pharmaceuticals for the prevention, treatment, management, diagnosis and prognosis of autoimmune, metastatic, hematologic, oncologic, ocular and neurologic diseases, conditions and disorders; biopharmaceuticals and pharmaceuticals for the prevention, treatment, management, diagnosis and prognosis of diseases, conditions and disorders associated with misfolded proteins; biopharmaceuticals and pharmaceuticals for the prevention, treatment, management, diagnosis and prognosis of diseases, conditions and disorders affecting the central nervous system; biopharmaceuticals and pharmaceuticals for the prevention, treatment, management, diagnosis and prognosis of amyloidosis, psoriasis, psoriatic arthritis, rheumatoid arthritis, dermatitis, host and graft rejections, Alzheimer's and Parkinson's-disease associated neuropsychiatric disorders, insulin resistance, metabolic syndrome and diabetes | |